½ÃÀ庸°í¼­
»óǰÄÚµå
1498667

¼¼°èÀÇ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Cardiac Troponin Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 49¾ï 5,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â ¾à 111¾ï 7,000¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³â CAGRÀº 9.46%ÀÔ´Ï´Ù.

½É±Ù Æ®·ÎÆ÷´ÑÀº ½É±Ù ¼¼Æ÷¿¡¼­ ±ÙÀ° ¼öÃà¿¡ Áß¿äÇÑ ´Ü¹éÁú º¹ÇÕüÀÔ´Ï´Ù. Æ®·ÎÆ÷´Ñ T, Æ®·ÎÆ÷´Ñ I, Æ®·ÎÆ÷´Ñ CÀÇ ¼¼ °¡Áö ÇÏÀ§ ´ÜÀ§·Î ±¸¼ºµË´Ï´Ù. ÀÌ ´Ü¹éÁúÀÇ Ç÷Áß ³óµµ Áõ°¡´Â ½É±Ù°æ»ö(½ÉÀ帶ºñ)À» Áø´ÜÇÏ´Â Áß¿äÇÑ ¹ÙÀÌ¿À¸¶Ä¿ÀÔ´Ï´Ù. ½É±Ù¼¼Æ÷°¡ ¼Õ»óµÇ¸é Æ®·ÎÆ÷´ÑÀÌ Ç÷ÁßÀ¸·Î ¹æÃâµÇ±â ¶§¹®¿¡ ½ÉÀå ¼Õ»ó¿¡ ´ëÇÑ ¹Î°¨ÇÏ°í Æ¯ÀÌÀûÀÎ ¸¶Ä¿°¡ µË´Ï´Ù. ÀÌ ¼öÄ¡¸¦ ÃøÁ¤ÇÔÀ¸·Î½á ÀÇ·áÁøÀº ½ÉÀ帶ºñÀÇ ½É°¢¼ºÀ» Æò°¡Çϰí Ä¡·á ¹æÄ§À» °áÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. Æ®·ÎÆ÷´ÑÀº ±Þ¼º °ü»óµ¿¸Æ ÁõÈıºÀÇ Á¶±â ¹ß°ßÀ» À§ÇØ ÀÀ±ÞÀÇ·á ¹× ½ÉÀåÇп¡¼­ ÇʼöÀûÀÎ ÅøÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ

½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀåÀº ½É±Ù°æ»ö, ½ÉºÎÀü µî ½ÉÇ÷°ü ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Áúº´ ºÎ´ã Áõ°¡, Àα¸ °í·ÉÈ­, °Ç°­¿¡ ÇØ·Î¿î »ýȰ½À°ü µîÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ±â¼ú ¹× ÀÓ»ó °Ë»ç Áø´ÜÀÇ ¹ßÀüÀ¸·Î ¸Å¿ì ¹Î°¨ÇÑ Æ®·ÎÆ÷´Ñ ÃøÁ¤¹ýÀÌ °³¹ßµÇ¾î ½É±Ù ÁúȯÀ» Á¶±â¿¡ Á¤È®ÇÏ°Ô °¨ÁöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ȯÀÚ Ä¡·á¸¦ °³¼±ÇÏ°í ½ÃÀå º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¹¹æÀû °Ç°­°ü¸®¿Í °íÀ§Ç豺¿¡ ´ëÇÑ Á¤±âÀûÀÎ ½É±Ù °ËÁø¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½É±Ù Æ®·ÎÆ÷´Ñ¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±Þ¼º °ü»óµ¿¸Æ ÁõÈıº»Ó¸¸ ¾Æ´Ï¶ó ½ÉºÎÀü ¹× ÆÐÇ÷Áõ°ú °°Àº Áúȯ¿¡ ´ëÇÑ Æ®·ÎÆ÷´Ñ ºÐ¼®ÀÇ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀåÀÇ ¹üÀ§¿Í °¡´É¼ºÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó ¹× Áø´Ü ¼­ºñ½º Á¢±Ù¼ºÀ» °­È­ÇÏ·Á´Â Á¤ºÎÀÇ ±¸»óÀº Æ®·ÎÆ÷´Ñ °Ë»çÀÇ °¡¿ë¼º°ú °æÁ¦¼ºÀ» ³ô¿© ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ±×·¯³ª °í°¨µµ Áø´Ü ÀåºñÀÇ Çʿ伺°ú À§¾ç¼º °¡´É¼ºÀÌ ÇâÈÄ ¼ö³â°£ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

Á¶»ç ¸®Æ÷Æ®´Â Porter's Five Forces ¸ðµ¨, ½ÃÀåÀÇ ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» Ä¿¹öÇϰí ÀÖ½À´Ï´Ù. ÀÌ ÅøÀº ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇϰí, ¼¼°è ·¹º§¿¡¼­ÀÇ °æÀï ¸Å·ÂÀ» Æò°¡Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ ÅøÀº ¼¼°èÀÇ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ½É±Ù Æ®·ÎÆ÷´Ñ »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ÀüüÀûÀÎ ¾îÇÁ·ÎÄ¡¸¦ Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ·¹º§ ºÎ¹®¿¡ °üÇÑ »ó¼¼ µ¥ÀÌÅ͸¦ Á¦°øÇϰí, ÀÌ¿¡ µû¶ó Àü·«°¡°¡ ÇâÈÄ ±âȸ¿Í ÇÔ²² °¢°¢ÀÇ Á¦Ç° ¹× ¼­ºñ½ºÀÇ ´ë»óÃþÀ» ½Äº°Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù.

Æ®·ÎÆ÷´Ñ À¯Çüº°

  • Æ®·ÎÆ÷´Ñ I
  • Æ®·ÎÆ÷´Ñ T
  • Æ®·ÎÆ÷´Ñ C

ȯ°æº°

  • ½ÃÇè±â°ü
  • POC(Point-of-Care) °Ë»ç

ÀûÀÀÁõº°

  • ½É±Ù°æ»ö
  • ¿ïÇ÷¼º½ÉºÎÀü
  • ±Þ¼º °ü»óµ¿¸Æ ÁõÈıº
  • ±âŸ(½É±ÙÁõ µî)

ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø¡¤Å¬¸®´Ð
  • Áø´Ü ¿¬±¸¼Ò
  • ÀçÅÃÀÇ·á
  • ±âŸ(¿¬±¸±â°ü µî)

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ & ¾ÆÇÁ¸®Ä«¿¡¼­ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀåÀÇ ÇöÀç ¹× ÇâÈÄ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤¡¤¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. Value Market ResearchÀÇ Á¶»çÆÀÀÌ °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü ¸®Æ÷Æ®¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå ½É±Ù Æ®·ÎÆ÷´Ñ - »ê¾÷ ºÐ¼®

  • ¼­·Ð - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå ºÐ¼® : Æ®·ÎÆ÷´Ñ À¯Çüº°

  • Æ®·ÎÆ÷´Ñ À¯Çüº° °³¿ä
  • Æ®·ÎÆ÷´Ñ À¯Çüº° ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • Æ®·ÎÆ÷´Ñ I
  • Æ®·ÎÆ÷´Ñ T
  • Æ®·ÎÆ÷´Ñ C

Á¦6Àå ¼¼°èÀÇ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå ºÐ¼® : ȯ°æº°

  • ȯ°æº° °³¿ä
  • ȯ°æº° ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ½ÃÇè±â°ü
  • POC(Point-of-Care) °Ë»ç

Á¦7Àå ¼¼°èÀÇ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

  • ÀûÀÀÁõº° °³¿ä
  • ÀûÀÀÁõº° ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ½É±Ù°æ»ö
  • ¿ïÇ÷¼º½ÉºÎÀü
  • ±Þ¼º °ü»óµ¿¸Æ ÁõÈıº
  • ±âŸ(½É±ÙÁõ µî)

Á¦8Àå ¼¼°èÀÇ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÇÀû¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • º´¿ø¡¤Å¬¸®´Ð
  • Áø´Ü ¿¬±¸¼Ò
  • ÀçÅÃÀÇ·á
  • ±âŸ(¿¬±¸±â°ü µî)

Á¦9Àå ¼¼°èÀÇ ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ½É±Ù Æ®·ÎÆ÷´Ñ ±â¾÷ÀÇ °æÀï ±¸µµ

  • ½É±Ù Æ®·ÎÆ÷´Ñ ½ÃÀåÀÇ °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦11Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • F. Hoffmann-La Roche Ltd.
  • BioMeRieux SA
  • Abbott Laboratories
  • Siemens Healthineers India
  • Eurolyser Diagnostica GmbH
  • QuidelOrtho Corporation
  • Beckman Coulter Inc.
  • Response Biomedical Corporation
  • LifeSign LLC
KSA 24.06.27

The global demand for Cardiac Troponin Market is presumed to reach the market size of nearly USD 11.17 Billion by 2032 from USD 4.95 Billion in 2023 with a CAGR of 9.46% under the study period 2024-2032.

Cardiac troponin is a protein complex in heart muscle cells crucial for muscle contraction. It comprises three subunits: troponin T, troponin I, and troponin C. Elevated levels of this protein in the blood are a key biomarker for diagnosing myocardial infarction (heart attack). When heart muscle cells incur damage, troponin is released into the bloodstream, rendering it a highly sensitive and specific marker for heart injury. Measuring levels helps healthcare providers assess the severity of a heart attack and guide treatment decisions. It is a vital tool in emergency medicine & cardiology for the early detection of acute coronary syndromes.

MARKET DYNAMICS

The cardiac troponin market is influenced by the increasing prevalence of cardiovascular diseases worldwide, such as myocardial infarction and heart failure. Rising disease burden, aging populations, and unhealthy lifestyles drive market growth. Advancements in medical technology and laboratory diagnostics have led to the development of exceptional sensitive troponin assays, enabling earlier and more accurate detection of myocardial injury. These technological innovations enhance patient care and drive market adoption. Additionally, the increasing emphasis on preventive healthcare and routine cardiac screening among high-risk populations further boosts the demand for cardiac troponin. Moreover, the expanding application of troponin assays beyond acute coronary syndromes to include conditions like heart failure and sepsis broadens the market's scope and potential. Efforts by the government to enhance healthcare infrastructure and accessibility to diagnostic services bolster market expansion by augmenting the availability and affordability of troponin testing. However, the need for highly sensitive diagnostic equipment and potential false-positive results may challenge the cardiac troponin market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cardiac Troponin. The growth and trends of Cardiac Troponin industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cardiac Troponin market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Troponin Type

  • Troponin I
  • Troponin T
  • Troponin C

By Setting

  • Laboratory Setting
  • Point-of-Care (POC) Testing

By Indication

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Others (Cardiomyopathy, etc.)

By End-user

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Homecare Settings
  • Others (research Institutes, etc.)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cardiac Troponin market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cardiac Troponin market include F. Hoffmann-La Roche Ltd., BioMeRieux SA, Abbott Laboratories, Siemens Healthineers India, Eurolyser Diagnostica GmbH, QuidelOrtho Corporation, Beckman Coulter Inc., Response Biomedical Corporation, LifeSign LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CARDIAC TROPONIN - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Troponin Type
    • 3.7.2 Market Attractiveness Analysis By Setting
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By End-user
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CARDIAC TROPONIN MARKET ANALYSIS BY TROPONIN TYPE

  • 5.1. Overview By Troponin Type
  • 5.2. Historical and Forecast Data Analysis By Troponin Type
  • 5.3. Troponin I Historic and Forecast Sales By Regions
  • 5.4. Troponin T Historic and Forecast Sales By Regions
  • 5.5. Troponin C Historic and Forecast Sales By Regions

6. GLOBAL CARDIAC TROPONIN MARKET ANALYSIS BY SETTING

  • 6.1. Overview By Setting
  • 6.2. Historical and Forecast Data Analysis By Setting
  • 6.3. Laboratory Setting Historic and Forecast Sales By Regions
  • 6.4. Point-of-Care (POC) Testing Historic and Forecast Sales By Regions

7. GLOBAL CARDIAC TROPONIN MARKET ANALYSIS BY INDICATION

  • 7.1. Overview By Indication
  • 7.2. Historical and Forecast Data Analysis By Indication
  • 7.3. Myocardial Infarction Historic and Forecast Sales By Regions
  • 7.4. Congestive Heart Failure Historic and Forecast Sales By Regions
  • 7.5. Acute Coronary Syndrome Historic and Forecast Sales By Regions
  • 7.6. Others (Cardiomyopathy, etc.) Historic and Forecast Sales By Regions

8. GLOBAL CARDIAC TROPONIN MARKET ANALYSIS BY END-USER

  • 8.1. Overview By End-user
  • 8.2. Historical and Forecast Data Analysis By End-user
  • 8.3. Hospitals & Clinics Historic and Forecast Sales By Regions
  • 8.4. Diagnostic Laboratories Historic and Forecast Sales By Regions
  • 8.5. Homecare Settings Historic and Forecast Sales By Regions
  • 8.6. Others (research Institutes, etc.) Historic and Forecast Sales By Regions

9. GLOBAL CARDIAC TROPONIN MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE CARDIAC TROPONIN COMPANIES

  • 10.1. Cardiac Troponin Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF CARDIAC TROPONIN INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. F. Hoffmann-La Roche Ltd.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. BioMeRieux SA
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Abbott Laboratories
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Siemens Healthineers India
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Eurolyser Diagnostica GmbH
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. QuidelOrtho Corporation
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Beckman Coulter Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Response Biomedical Corporation
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. LifeSign LLC
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦